Leptospira grippotyphosa (L. grippotyphosa)

Leptospira grippotyphosa is a pathogenic spirochete and a significant serovar within the genus Leptospira, recognized as a primary causative agent of leptospirosis, a globally distributed zoonotic disease [5, 12, 17]. The bacterium is typically maintained in wildlife reservoirs such as raccoons, opossums, and voles, and is transmitted to humans and domestic animals through contact with water or soil contaminated by the urine of these carriers [13, 17, 18]. Following entry into the host through mucous membranes or skin abrasions, the organism disseminates hematogenously to colonize multiple organs, showing a particular tropism for the renal tubules where it can persist despite an immune response [13, 16]. Clinical presentations of L. grippotyphosa infection range from a mild flu-like syndrome to severe multiorgan failure, including jaundice and acute renal failure, commonly referred to as Weil's disease [16, 17]. Therapeutic management involves the administration of broad-spectrum antibiotics, such as penicillin and doxycycline, which disrupt essential bacterial processes like cell wall and protein synthesis [1, 4, 8]. However, treatment challenges include the potential for the Jarisch-Herxheimer reaction upon initiation of therapy and the limited cross-protection provided by current serovar-specific vaccines [5, 8, 10].

Other names

Leptospira interrogans serovar GrippotyphosaLeptospira kirschneri serovar GrippotyphosaSerovar GrippotyphosaL. grippotyphosa

Antibiotics targeting this organism act by inhibiting bacterial cell wall synthesis (beta-lactams), inhibiting protein synthesis (tetracyclines and aminoglycosides), or interfering with DNA gyrase activity (fluoroquinolones) [4, 5, 8].